Morphic Therapeutic is developing a new generation of oral integrin therapies to treat autoimmune, cardiovascular and metabolic diseases. Integrins are receptors found at the cell membrane and are involved in many cellular processes by signaling bi-directionally. Malfunctions in the integrins are linked with disease. Using their proprietary MInT drug discovery platform and knowledge from integrin research leaders, Morphic is in the position to target all 24 known human integrins to stabilize their conformation or to activate or inhibit their activity to modify disease. One molecule (MORF-057) is already in Phase I clinical trials for inflammatory bowel disease.

<p>Morphic Therapeutic is developing a new generation of oral integrin therapies to treat autoimmune, cardiovascular and metabolic diseases. Integrins are receptors found at the cell membrane and are involved in many cellular processes by signaling bi-directionally. Malfunctions in the integrins are linked with disease. Using their proprietary MInT drug discovery platform and knowledge from integrin research leaders, Morphic is in the position to target all 24 known human integrins to stabilize their conformation or to activate or inhibit their activity to modify disease. One molecule (MORF-057) is already in Phase I clinical trials for inflammatory bowel disease.</p>


Morphic Therapeutic

Founded: 2016
Location: Waltham, MA
Employee range: 50 - 200
Clinical stage: Clin2
Therapy area: Ulcerative colitis, Crohn&#x27;s
Drug types: GI, ONC, CVV
Lead product: MORF-057
Funding: $240M stock May 2023; $245M stock Mar 2021; $90M IPO Jun 2019; $80M B Sep 2018; $51.5M A Jul 2016

Drug notes:

About:

Jobs: